The influence of postoperative hyperthermic intraperitoneal perfusion chemotherapy on serum tumor markers in advanced adenocarcinoma of esophagogastric junction
10.3760/cma.j.issn.1007-631X.2018.01.019
- VernacularTitle:进展期食管胃交界部腺癌患者术后腹腔热灌注化疗对血清肿瘤标志物的影响
- Author:
Zhizhong ZHANG
1
;
Shoumiao LI
;
Baozhong LI
;
Zhiqiang LIU
;
Wei ZHANG
;
Yunjie WAN
;
Ganshu XIA
Author Information
1. 安阳市肿瘤医院外科
- Keywords:
Stomach neoplasms;
Carcinoembryonic antigen;
Chemotherapy,cancer,regional perfusion;
Paclitaxel
- From:
Chinese Journal of General Surgery
2018;33(1):65-67
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the changes of CEA,CA19-9,CA72-4 of patients with advanced adenocarcinoma of the esophagogastric junction (AEGJ) who received ultra-early precise hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) with paclitaxel (PTX) after radical surgery.Methods From Jul 2014 to Dec 2015 postoperative advanced AEGJ patients were divided to receive ultraearly precise HIPEC (87 cases,HIPEC group) and conventional therapy group (85 cases) in early stage after radical surgery.Serum levels of CEA,CA19-9 and CA72-4 were examined on preoperative day 1 and postoperative day 9.Results On post-op day 9,the level of CEA,CA19-9 and CA72-4 was (2.8 ± 1.3)ng/ml,(22 ±8)IU/ml,(4.1 ± 1.9)IU/ml in HIPEC group,while that was (3.4 ± 1.2)ng/ml,(25 ±11) IU/ml,(4.8 ± 2.1) IU/ml in control group respectively (t =2.453,P =0.015;t =2.241,P =0.026;t =2.154,P =0.033).Conclusion Ultra-early PTX-based HIPEC with advanced AEGJ after radical surgery lowers serum tumor makers of CEA,CA19-9,CA72-4,reducing body's tumor burden.
